Back to news

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

Business Wire•16/11/2026•08:30 ET
0

Key Highlights

  • ➤$50 million Meiji investment priced at $20.27 per share, an 80% premium
  • ➤Meiji receives 7.9% of Arcturus shares outstanding after transaction
  • ➤Proceeds accelerate ARCT-2601 development for OTC deficiency
  • ➤Exclusive ARCT-154 license covers an undisclosed therapeutic area
  • ➤Pandemic preparedness MOU targets potential collaboration and licensing in Japan

Expert Statements

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics

“We are pleased to expand our relationship with Meiji as we advance innovative mRNA medicines and seek to deliver value to patients. The investment, together with the license agreement and the pandemic preparedness MOU, reflects Meiji’s confidence in our development capabilities and the potential of our technology platform.”

Joseph Payne, President and Chief Executive Officer of Arcturus Therapeutics

“Alongside our CF program, these proceeds will be used to accelerate development of ARCT-2601 for OTC deficiency, the first mRNA therapeutic to utilize our LUNAR 2.0™ delivery platform.”

Arcturus Therapeutics Announces $50 Million Investment by Meiji Seika Pharma as Part of Expanded Collaboration

$50 Million Strategic Investment in Arcturus at an 80% Premium

Get started

Create a free account to read the full story.

Sign Up

Already have an account? Log in